SCHEMBL1423909

SCHEMBL1423909

CC(C)Nc1cc(-c2cc3cnccc3c(NCCO)n2)ccn1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCH P24723 9/20 0.72
PRKCD Q05655 10/20 0.70
PRKD1 Q15139 9/20 0.70
PRKCA P17252 8/20 0.70
PRKCE Q02156 8/20 0.68
PRKCQ Q04759 7/20 0.68
PRKCB P05771 4/20 0.53
ROCK2 O75116 2/20 0.53
ROCK1 Q13464 2/20 0.53
PKN1 Q16512 2/20 0.53
PKN2 Q16513 2/20 0.53
CYP1A2 P05177 1/20 0.53
LATS1 O95835 1/20 0.45
LATS2 Q9NRM7 1/20 0.45
FLT3 P36888 1/20 0.41
PRKD2 Q9BZL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1424097 0.88 PRKCH (0.69) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL8138669 0.84 PRKCH (1.00) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL1424173 0.82 PRKCD (0.67) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL1423983 0.82 PRKCH (0.62) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL8125988 0.82 PRKCD (1.00) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL1423990 0.82 PRKD1 (1.00) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL3327608 0.82 PRKCH (1.00) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL1424712 0.81 PRKCD (0.76) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL8131585 0.78 PRKCD (0.62) PRKCHPRKCDPRKD1PRKCAPRKCE
SCHEMBL1424518 0.78 PRKCD (0.72) PRKCHPRKCDPRKD1PRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142685-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-06-07 US disclosed
US-20120142685-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-06-07 US disclosed
US-20120142685-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-06-07 US disclosed
EP-2144909-B1 [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-23 EP disclosed
EP-2144909-B1 [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-23 EP disclosed
EP-2144909-A1 [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS Novartis Ag (CH) 2010-01-20 EP disclosed
WO-2008122615-A1 [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2008-10-16 WO disclosed
WO-2008122615-A1 [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142685-A1 ORGANIC COMPOUNDS MARK1, PKN1, MARK2 PRKCH 102/4885PRKCD 127/4885PRKD1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.